Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (171-180 of 344) with videos related to

Pageof 35
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 11, 2019
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancerAkinori Sasaki, Yoshiaki Nakamura, Saori Mishima, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 7, 2022
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancerHirotaka Hasegawa, Kohei Shitara, Shuji Takiguchi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 10, 2021
Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapyTakahiro Ishii, Ayako Suzuki, Takeshi Kuwata, et al.
International Journal of Clinical Oncology|November 14, 2023
Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access studyKohei Shitara, Kensei Yamaguchi, Kei Muro, et al.
Investigational New Drugs|December 5, 2018
First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumorsToshihiko Doi, Kiyotaka Yoh, Kohei Shitara, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2018
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancerHideaki Bando, Hideki Shimodaira, Kazumasa Fujitani, et al.
The Lancet. Oncology|June 27, 2020
Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trialAkihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 2, 2024
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaKohei Shitara, Rui-Hua Xu, Jaffer A Ajani, et al.
Journal for Immunotherapy of Cancer|February 2, 2019
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancerSaori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, et al.
Cancer Science|January 21, 2010
Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective studyKohei Shitara, Keitaro Matsuo, Shunzo Hatooka, et al.
Pageof 35

Showing results (171-180 of 344) with videos related to

Sort By:
Pageof 35
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 11, 2019
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancerAkinori Sasaki, Yoshiaki Nakamura, Saori Mishima, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 7, 2022
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancerHirotaka Hasegawa, Kohei Shitara, Shuji Takiguchi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 10, 2021
Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapyTakahiro Ishii, Ayako Suzuki, Takeshi Kuwata, et al.
International Journal of Clinical Oncology|November 14, 2023
Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access studyKohei Shitara, Kensei Yamaguchi, Kei Muro, et al.
Investigational New Drugs|December 5, 2018
First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumorsToshihiko Doi, Kiyotaka Yoh, Kohei Shitara, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2018
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancerHideaki Bando, Hideki Shimodaira, Kazumasa Fujitani, et al.
The Lancet. Oncology|June 27, 2020
Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trialAkihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 2, 2024
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaKohei Shitara, Rui-Hua Xu, Jaffer A Ajani, et al.
Journal for Immunotherapy of Cancer|February 2, 2019
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancerSaori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, et al.
Cancer Science|January 21, 2010
Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective studyKohei Shitara, Keitaro Matsuo, Shunzo Hatooka, et al.
Pageof 35